MedTrace Logo

CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes

NCT06087328 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-11-26

Study results available
· View outcomes & findings →

Summary

Many people smoke cigarettes and use e-cigarettes, and have a hard time stopping. Nicotine replacement therapy medications, such as nicotine patches and lozenges, have been shown to help people quit e-cigarette use. The purpose of the present study is to see how well nicotine patches and lozenges help people quit both smoking and vaping, and to determine if higher doses of the medication work best.

Conditions

  • Smoking Cessation
  • Electronic Cigarette Use
  • Cigarette Smoking

Interventions

DRUG

Regular Nicotine patch and lozenge dose

1mg patch, qd + 4mg lozenge prn \[minimum of 5 \& up to 20 per day\]

DRUG

Augmented Nicotine patch and lozenge dose

21mg patch + 14mg patch qd + 4mg lozenge prn \[minimum of 5 \& up to 30 per day\] OR 2 x 21mg patches qd + 4mg lozenges prn \[minimum of 5 \& up to 40 per day\]

Sponsors & Collaborators

  • American Cancer Society, Inc.

    collaborator OTHER

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Amanda Palmer · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-05
Primary Completion
2024-11-05
Completion
2024-11-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06087328 on ClinicalTrials.gov